Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Faster sales but less profits for Probi

The probiotic company increases its turnover, and the net results are twice as large as last year.

Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

Test if you carry the fat virus

In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.

Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal

Success fee to Bioinvent and partner

The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.

A smart company takes care of its best

Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.

Almost 150 will leave Coloplast

The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.

Hormones make children fat

A new Danish million project will define the connection between hormons and obesity amongst children.

Biovitrum sells UK part

Biovitrum will soon spin-out a British subsidary

Biotech goes white and bright

White biotech could become Denmark's next blossoming business area.

Top modern lab to Sahlgrenska

The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.

Respiratorius hunts millions

The biopharmaceutical company Respiratorius has got a new CEO, who starts a public new share issue to catch almost SEK ten million.

Think outside the... brain

Riitta Hari from the Brain Research Unit at the Helsinki University of Technology has recently stated that the mind is more than just the brain.

Eli Lilly writes biotech fine history

The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.

Swedish multi competent machine soon launched

The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.

Abbott expands by acquisition

An acquisition gives Abbott a leadership position in another large and growing medical device segment.

LEO Pharma - International Clinical Trial Manager

Medicult disclaims Swedish offer

The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.

Crafoord Prize to an American and two Japanese

Today the Royal Swedish Academy of Sciences announces the laureates of the Crafoord Prize in Polyarthritis 2009.

Ten recieve the Venture Cup West Prize

At this year´s Venture Cup West awards the 10 best business ideas in Venture Cup West 08/09 were chosen, receiving SEK 10 000 each.

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.